Argus Research Upgrades Biogen to Buy, Announces $280 Price Target
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsUpgradesPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Argus Research analyst Jasper Hellweg upgrades Biogen (NASDAQ:BIIB) from Hold to Buy and announces $280 price target.
Argus Research analyst Jasper Hellweg upgrades Biogen (NASDAQ:BIIB) from Hold to Buy and announces $280 price target.
More on BIIB
Benzinga
Eisai And Biogen Present Findings From Analysis Of Lecanemab-Irmb Treatment And α-Syn Co-Pathology In Cerebrospinal Fluid Substudy Of Clarity AD In Early Alzheimer’s Disease, At CTAD ConferenceLecanemab showed favorable results on clinical assessment scores at 18 months, including among individuals with early Alzheimer’s disease (AD) who were α-synuclein positive, a subgroup associated…
